#United States #New York #Shareholders #Securities Law #Altimmune

Investors of Altimmune, Inc. Urged to Take Action

In a significant development, Altimmune, Inc. (NASDAQ: ALT) is currently embroiled in a lawsuit concerning alleged violations of securities laws. This situation has prompted The Gross Law Firm to reach out to shareholders who purchased Altimmune shares during a specified class period, encouraging them to take necessary steps to protect their legal rights.

The allegations in this case center on misleading statements made by Altimmune regarding the performance of its clinical trials. Specifically, the lawsuit stems from a press release that Altimmune published on June 26, 2025, announcing topline results from the IMPACT Phase 2b trial of Pemvidutide, a treatment aimed at the condition known as MASH. Despite the company's previous optimistic projections regarding the trial's outcomes, the results revealed a significant failure to meet the expectations set forth, particularly regarding the statistical significance of fibrosis reduction.

During this trial, while some positive trends in fibrosis improvement were noted, a higher-than-anticipated response from the placebo group resulted in the failure to achieve the necessary statistical significance for the primary endpoint. This alarming news had an immediate and dramatic impact on Altimmune's stock price, which plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, marking a staggering decline of 53.2% in a mere 24-hour period.

Shareholders who purchased ALT shares during the class period, which is defined as August 10, 2023, to June 25, 2025, are strongly encouraged to reach out to The Gross Law Firm. They can assist shareholders in the process of potentially becoming lead plaintiffs in this class action lawsuit. Importantly, purchasing shares during the specified period is not a requirement to participate in any recovery resulting from this case.

The Gross Law Firm specializes in protecting the rights of investors who have lost funds due to deceptive business practices. By swiftly addressing these issues, they aim to hold companies accountable for any misinformation that has resulted in financial losses for shareholders. For those interested in participating, the registration deadline is fast approaching on October 6, 2025.

Next Steps for Affected Shareholders

After registering, shareholders will be included in a portfolio monitoring service that will keep them updated throughout the litigation's progress. It is vital that affected parties act promptly to ensure their eligibility for any recovery, as time is of the essence in these legal matters. There are no costs to register or participate in this case, creating an opportunity for investors to explore their options without financial risk.

The Gross Law Firm stands out as a well-respected leader in class action lawsuits and is devoted to enforcing investor rights, making it essential for Altimmune shareholders to take advantage of this chance to safeguard themselves from further harm.

For further information or to register as a shareholder, interested parties can visit The Gross Law Firm's website.

In conclusion, the unfolding situation with Altimmune is an important reminder for all investors to stay vigilant and informed about the companies in which they choose to invest. The complexities of the financial markets necessitate proactive engagement to protect one’s interests, especially when facing potential violations of securities law.